1Snyder JJ, Foley RN,Gilbertson DT, et al. Hemoglobin levels and erythropoietin dose in hemodialysis and perito- neal dialysis patient in the United States[J]. J Am Soc Nephrol,2004,15 (1) :174-179.
3Jaureguy M,Choukroun G. Factors affecting the response to erythropoiesis-stimulating agents[J]. Nephrol Ther, 2006,2 Suppl4 : S274-282.
4Balla J ,Jeney V,Varga Z,et al. Iron hemeostasis in chron- ic inflammation[J]. Acta Physiol Hung, 2007,94(1/2) : 95- 106.
二级参考文献8
1Bargman J, Thorpe K, Churchill D. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol, 2001, 12: 2158-2162.
2Shemin D, Bostom A, Laliberty P, et al. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis, 2001, 38: 85-90.
3Van Biesen W, Vanholder R, Veys N, et al. An evaluation of an integrative care approach for end-stage renal disease patients. J Am Soc Nephrol, 2000, 11: 116-125.
4Li P, Chow K-M, Wong T, et al. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. Ann Intern Med, 2003, 139: 105-112.
5Suzuki H, Kanno Y, Sugahara S, et al. Effects of an angiotensin Ⅱ receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis, 2004, 43: 1056-1064.
6Jassal S, Lok C, Walele A, et al. Continued transplant immunosuppression may prolong survival after return to peritoneal dialysis: results of a decision analysis. Am J Kidney Dis, 2002, 40: 178-183.
7Maiorca R, Brunori G, Zubani R, et al. Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients. A longitudinal study. Nephrol Dial Transplant, 1995, 10: 2295-2305.
8Jansen M, Hart A, Korevaar J, et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int, 2002, 62: 1046-1053.
